source
- Camurus’ second CRL for acromegaly drug; Teva details workforce cutsPlus, news about a drug shortages report and Axplora: 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer. T…Endpoints · 1mo ago↗ source
- Novartis RNA drug acquired in $12B Avidity deal notches a trial winThe data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.BioPharma Dive · 1mo ago↗ source
- STAT+: Novartis doubles down on molecular glue strategySeniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The ReadoutSTAT · 1mo ago↗ source